JDRF’s research goal is to discover, develop, and deliver advances that progressively remove the impact of type 1 diabetes (T1D) from people’s lives until we achieve a world without T1D. As the global leader in the fight against T1D, JDRF’s research programs are comprehensive and reflect our strategic plan to bring about a continuous flow of life-changing therapies and, ultimately, a cure for T1D. JDRF is driving research across the entire scientific spectrum, from discovery in the laboratory to delivery of new technologies and treatments to people with T1D.
JDRF Research Funding Overview
JDRF is currently sponsoring more than $450 million in scientific research in 17 countries. Since its founding in 1970, JDRF has funded more than $1.7 billion in diabetes research and has dramatically advanced the T1D scientific frontier and the management of this disease.
More than 80 percent of JDRF’s expenditures directly support research and research-related education. JDRF maintains one of the best records among nonprofits of using supporters’ contributions effectively.
In 2012, JDRF supported more than 50 clinical studies, evaluating new therapies and treatments for T1D and seeking to better understand the disease’s cause and progression. This growing emphasis on clinical trials testifies to JDRF’s commitment to moving beyond scientific discovery to delivering solutions to better treat and cure T1D.
JDRF’s Research Goals
JDRF is committed to progressively removing the impact of T1D from people’s lives. JDRF is focused on delivering a sustained stream of new, life-changing therapies from the near term to the long term, with the ultimate goal of a world without T1D.
JDRF’s near- to mid-term goals include delivering:
• an automated low-glucose suspend artificial pancreas system, which predicts and prevents severe blood-glucose lows;
• a treat-to-range artificial pancreas system, which automatically keeps blood-glucose levels in a specified range;
• the use of existing type 2 diabetes drugs to improve blood-glucose control in people with T1D compared to the use of insulin alone;
• the use of donated human islets as a treatment for low–blood glucose unawareness.
JDRF’s long-term goals include delivering:
• a beta cell encapsulation product providing insulin independence for more than a year without the need for chronic immunosuppression;
• novel therapies for beta cell survival and immune modulation that when used in combination can extend the period of insulin independence after diagnosis for more than two years;
• advanced-generation artificial pancreas systems such as those that deliver two hormones and those that have full (24-hour) automation features that further improve glycemic control;
• a glucose responsive insulin that provides glycemic control with a single shot per day, or less often;
• novel therapies that improve eye disease in people with T1D;
• therapies that prevent or delay the onset of insulin dependence for at least two years in people with autoantibodies for T1D.
2012 JDRF Research Funding
|Cure Research||$65.1 million|
|Beta Cell Health & Regeneration Therapies||$23.9 million|
|Immune Therapies||$6.8 million|
|Beta Cell Encapsulation Therapies||$10.4 million|
|Cure Biomarkers and Imaging Tools||$17.2 million|
|Cure Transportfolio Projects||$6.8 million|
|Treat Research||$35.7 million|
|Artificial Pancreas Systems||$12.4 million|
|Glucose-Control Therapies||$2.5 million|
|Complications Prevention and Treatment Therapies||$20.8 million|
|Prevention Therapies Research||$8.2 million|
|General Research Projects||$1 million|
|TOTAL 2012 RESEARCH FUNDING||$110 million|